CORY RABE: Open Payments
NPI 1619218302 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,767 in 183 payments from 16 companies in 2025. Trend: 2023 $1,709 · 2024 $1,632 · 2025 $2,767
Food & beverage: $2,652Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $391 |
| Otsuka America Pharmaceutical, Inc. | 27 | $339 |
| Teva Pharmaceuticals USA, Inc. | 24 | $299 |
| Alkermes, Inc. | 15 | $281 |
| E.R. Squibb & Sons, L.L.C. | 24 | $275 |
| Janssen Pharmaceuticals, Inc | 10 | $240 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $187 |
| Neurocrine BioSciences, Inc. | 13 | $164 |
| Lundbeck LLC | 7 | $157 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
Products named: VRAYLAR, REXULTI, COBENFY, ARISTADA, SPRAVATO, UZEDY, CAPLYTA, ABILIFY MAINTENA.
Industry payments across NE — which companies pay providers there.
